---
title: "BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262619711.md"
description: "According to TipRanks, Zelin is a 4-star analyst with an average return of 5.9% and a 36.51% success rate. Zelin covers the Healthcare sector, focusing on stocks such as I-MAB, Viking Therapeutics, and Verastem. I-MAB has an analyst consensus of Strong Buy, with a price target consensus of $7.80."
datetime: "2025-10-24T11:45:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262619711.md)
  - [en](https://longbridge.com/en/news/262619711.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262619711.md)
generator: "portal-rs"
---

# BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)

According to TipRanks, Zelin is a 4-star analyst with an average return of 5.9% and a 36.51% success rate. Zelin covers the Healthcare sector, focusing on stocks such as I-MAB, Viking Therapeutics, and Verastem.

I-MAB has an analyst consensus of Strong Buy, with a price target consensus of $7.80.

### Related Stocks

- [IMAB.US](https://longbridge.com/en/quote/IMAB.US.md)
- [NBP.US](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

- [NovaBridge net loss widens to $37.9 million in FY26 first half; R&D expenses more than doubled to $14.3 million](https://longbridge.com/en/news/296478660.md)
- [Pfizer Stock (PFE) Is a Buy despite Declining Revenues](https://longbridge.com/en/news/296787219.md)
- [Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?](https://longbridge.com/en/news/296816441.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [BioCardia Advances Helix Catheter Toward De Novo Approval](https://longbridge.com/en/news/296793880.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**